Association of pretreatment with antifungal medication and fungal resistance in the mycotic ulcer treatment trial I

JAMA Ophthalmol. 2015 Oct;133(10):1210-1. doi: 10.1001/jamaophthalmol.2015.2040.

Authors

N Venkatesh Prajna¹, Lalitha Prajna¹, Kieran S O'Brien², Catherine Q Sun², Nisha Acharya³, Thomas M Lietman³, Jennifer Rose-Nussbaumer⁴; Mycotic Ulcer Treatment Trial Group

Affiliations

¹ Aravind Eye Care System, Madurai, India.
² Francis I. Proctor Foundation, University of California, San Francisco.
³ Francis I. Proctor Foundation, University of California, San Francisco3Department of Epidemiology and Biostatistics, University of California, San Francisco4Department of Ophthalmology, University of California, San Francisco.
⁴ Francis I. Proctor Foundation, University of California, San Francisco4Department of Ophthalmology, University of California, San Francisco5Department of Optometry, University of California, Berkeley.

No abstract available

Publication types

Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Administration, Oral
Administration, Topical
Adult
Antifungal Agents / therapeutic use*
Aspergillosis / drug therapy*
Aspergillosis / microbiology
Aspergillus fumigatus / drug effects
Aspergillus fumigatus / isolation & purification
Corneal Ulcer / drug therapy*
Corneal Ulcer / microbiology
Double-Blind Method
Drug Resistance, Fungal*
Eye Infections, Fungal / drug therapy*
Eye Infections, Fungal / microbiology
Female
Fusariosis / drug therapy*
Fusariosis / microbiology
Fusarium / drug effects
Fusarium / isolation & purification
Humans
Male
Microbial Sensitivity Tests
Middle Aged
Natamycin / therapeutic use
Voriconazole / therapeutic use

Substances

Antifungal Agents
Natamycin
Voriconazole

Grants and funding